http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Lim, Hyeong-Seok,Ryu, Keun Won,Lee, Jun Ho,Kim, Young-Woo,Ju Choi, Il,Kim, Mi-Jung,Park, Young-Iee,Hwang, Aekyung,Park, Sook Ryun J.B. Lippincott Co. [etc.] 2015 The Journal of Clinical Pharmacology Vol.55 No.8
<P>S-1 is an oral 5-fluorouracil agent containing tegafur, 5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate. This study explored the pharmacokinetics of S-1 and pharmacokinetic changes after gastric surgery in patients with resectable gastric cancer who received pre- and postoperative S-1 plus docetaxel. Serial blood was drawn before and after gastrectomy from 37 patients for pharmacokinetic analysis. The pharmacokinetics of tegafur, 5-fluorouracil, and CDHP were analyzed by noncompartmental analysis (NCA) methods and by modeling. In modeling analysis, CHDP concentrations were incorporated in the model as a time-varying covariate that inhibits the clearance of 5-fluorouracil following an inhibitory Emax model. In NCA, the pharmacokinetics of tegafur and 5-FU before and after gastric surgery were similar, although average maximum concentrations of 5-FU were decreased with statistical significance after gastrectomy. Median Tmax of tegafur was shorter after surgery without statistical significance. In modeling analysis, tegafur was best fitted by mixed zero and first-order absorption. The only difference in the final pharmacokinetic model around gastrectomy was the presence of an absorption lag of 0.23 hours before surgery. Incorporation of CDHP concentrations significantly improved the model. Although some pharmacokinetic results showed statistically significant changes after gastrectomy, these differences seem to be too small to have any clinical implication.</P>
한국산 야생등줄쥐 (Apodemus Agrarius coreae)의 대뇌피질과 줄무늬체에서 Neuropeptide Y 면역반응신경세포의 분포
이경열(Kyoung-Youl Lee),박일권(Il-Kwon Park),송치원(Chi-Won Song),권효정(Hyo-Jung Kwon),박미선(Mi-Sun Park),김무강, 정영길(Young-Gil Jung),이강이(Kang-Iee Lee),이철호(Chun-Ho Lee),현병화(Byung-Hwa Hyun),최농훈(Nong-Hun Choe) 대한해부학회 2001 Anatomy & Cell Biology Vol.34 No.2
Neuropeptide Y (NPY)는 돼지의 뇌에서 처음 분리 추출된 이후 여러학자들에 의해 여러동물의 뇌에 존재함이 밝혀졌으 며 이런 NPY는 신경조절물질 또는 신경활성물질에 관여하는 것으로 있려져 있다. 본 연구에서는 한국산 야생등줄쥐 (apodemus agrarius cereae)의 대뇌피질과 줄무늬체에서의 NPY면역반응신경세포체의 분포를 관찰하고자 면역조직화학염 색을 실시하여 관찰하였던 바 다음과 같은 결론을 얻었다. 1. 야생등줄쥐의 대뇌피질에서 NPY면역반응신경세포체가 모든 층에서 출현하였으며 특히 V층과 VI층에 주로 분포하 였고 I층과 VI층에서는 드물게 나타났다. 2. 대뇌피질에서 NPY면역반응신경세포체의 모양은 타원형, 난원형, 뭇각형 등 다양하게 존재하였고 I층과 II층에서는 원 형과 타원형이 많았으며 V층과 VI층에서는 뭇각형이 많았다. 세포돌기는 두극형 또는 뭇극형으로 존재하였는데 그 세포돌기의 주행방향이 I층과 II층에서는 연질막 (pia mater)과 평행으로 III층에서 두극형의 세포는 수직방향으로 그 돌기가 뻗어 있었으며 VI층에서는 뇌량과 평행하게 주행하고 있었다. 세포체의 크기는 중간크기 (10~20 μm)의 세포가 대부분이고 20 μm 이상인 세포는 드물게 관찰되었다. 3. 대뇌피질의 부위별 분포는 후각뇌주위피질에서 그 수가 가장 많이 나타났고 두정피질에서 그 다음으로 많이 나타났 으며 팽대뒤피질에서는 가장 적은 것으로 나타났다. 그러나 섬피질에서는 갯수는 적으나 그 밀집도가 높았다. 두정피 질부위에서는 대개 III-VI층에 주로 분포하였고 전두피질에서는 다른 부위보다 II층에 많은 세포체가 존재하였다. 4. 줄무늬체에서의 NPY면역반응신경세포체는 꼬리-조가비핵에서만 관찰되었으며 뒷쪽으로 갈수록 그 수가 줄어들었고 중간부위에서는 NPY면역반응신경세포체가 배쪽내측부분에 많이 분포되어 있는 것을 볼 수 있었다. 5. 줄무늬체에서의 NPY면역반응신경세포체의 모양은 타원형, 난원형, 뭇각형 등 다양하였으나 주로 뭇각형이 많았으며 그 세포돌기도 사방으로 뻗어있었고 그 크기는 15~20 μm로 중간세포가 대부분이었다. Neuropeptide Y (NPY) was first isolated from porcine brain. This discovery has led some workers to study the distribution of this peptide in the central nervous system of various mammals. In this study examined the distribution pattern of NPY-immunoreactive (NPY-IR) neurons in the Striped Field Mouse (Apodemus agrarius coreae) cerebral cortex and striatum, using immunohistochemical method. The results obtained in this study were summarized as followings. 1. NPY-IR neurons distributed in all layer of cerebral cortex. The number of neurons were higher in layer V and VI than in layer I and IV. 2. The shape of neurons was predominantly round or oval in layer I and II, and triangular in layer V and VI. And the processes were parallel to pia mater in layer I and II and were vertical in layer III. 3. The highest number of NPY-IR neurons were found in the perirhinal cortex but a few distinct population were found in the retrosplenial cortex. 4. In stiatum NPY-IR neurons were observed only in caudate-putamen nucleus. 5. The Immunoreactive neurons in caudate-putamen varied in their shape, but most of them were triangular or multiform neurons had omnidirectional processes.
Kong, Sun-Young,Lim, Hyeong-Seok,Nam, Byung-Ho,Kook, Myeong-Cherl,Kim, Young-Woo,Won Ryu, Keun,Lee, Jun Ho,Choi, Il Ju,Lee, Jin Soo,Park, Young-Iee,Kim, Noe Kyeong,Park, Sook Ryun Future Medicine 2009 Pharmacogenomics Vol.10 No.7
<P>AIMS: S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. We evaluated the association between CYP2A6 polymorphisms and treatment outcome in metastatic gastric cancer patients treated with S-1 plus docetaxel. MATERIALS & METHODS: Chemonaive patients received S-1 40 mg/m(2) twice daily on days 1-14 and docetaxel 35 mg/m(2) on days 1 and 8 of a 3-week cycle. We analyzed the wild-type (W) allele (CYP2A6*1) and four variant (V) alleles that abolish or reduce enzyme activity (CYP2A6*4, *7, *9 and *10). A total of 50 patients were enrolled. RESULTS: The genotype frequencies were as follows: W/W (n=14, 28%), W/V (n=26, 52%) and V/V (n=0, 20%). Patients having fewer variant alleles had significantly better response rates (W/W vs W/V vs V/V=79 vs 65 vs 30%; p=0.04) and median progression-free survival (W/W vs W/V vs V/V=8.1 vs 6.9 vs 3.1 months; p=0.0009). CONCLUSION: Our findings showed that the CYP2A6 genotype correlated with the treatment efficacy of S-1-based chemotherapy in previously untreated metastatic gastric cancer patients.</P>
Eom, Bang Wool,Kim, Sohee,Kim, Ja Yeon,Yoon, Hong Man,Kim, Mi-Jung,Nam, Byung-Ho,Kim, Young-Woo,Park, Young-Iee,Park, Sook Ryun,Ryu, Keun Won The Korean Gastric Cancer Association 2018 Journal of gastric cancer Vol.18 No.1
Purpose: It has been reported that the survival of patients with locally advanced gastric cancer (LAGC) is better in East Asia countries than in developed western countries; however, the prognosis of LAGC remains poor. This study aimed to evaluate the effects of perioperative chemotherapy on the long-term survival of East Asia patients with LAGC. Materials and Methods: From October 2006 through August 2008, 43 patients with LAGC received perioperative S-1 combined with weekly docetaxel in a phase II study (neoadjuvant group). These patients were matched using propensity scores to patients who underwent surgery without neoadjuvant chemotherapy during the same period (surgery group). The surgical outcomes and long-term survivals were compared between the 2 groups. Results: After matching, 43 and 86 patients were included in the neoadjuvant and surgery groups, respectively, and there was no significant difference in their baseline characteristics. Although the operating time was longer in the neoadjuvant group, there was no significant difference in postoperative complications between the 2 groups. The neoadjuvant group had a significantly higher 5-year overall survival (OS) rate (73.3% vs. 51.1%, P=0.005) and a trend towards higher 5-year progression-free survival (PFS) (62.8% vs. 49.9%, P=0.145). In the multivariate analysis, perioperative chemotherapy was an independent factor for OS, with a hazard ratio of 0.4 (P=0.005) and a marginal effect on the PFS (P=0.054). Conclusions: Perioperative chemotherapy was associated with better long-term survival without increasing postoperative complications in the setting of D2 surgery for patients with LAGC, suggesting that perioperative chemotherapy can be a therapeutic option in East Asia countries.